On the other hand, in the NAE group, there was no significant difference in pathological therapeutic effect between tumor with PIK3CA mutations and tumor with PIK3CA wild-type (response rates 6.3% vs. 12.9%, p = 0.54; Table 3). This evidence concerns the gene PIK3CA and neoplasm.